Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Lessons from Jack Griffin and the "pathogenesis of peripheral nerve disease".
No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: a comparative analysis of different approaches during the first year of natalizumab discontinuation.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.
ATX-MS-1467 - Positive Immunological data in Multiple Sclerosis: Final Phase I/IIa data shows safety and tolerability, plus efficacy
FDA approves Ampyra to improve walking in adults with multiple sclerosis
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Concurrent saturation transfer contrast in in vivo brain by a uniform magnetization transfer MRI.
Olive oil phenols and neuroprotection.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Ocrelizumab in multiple sclerosis: risks and benefits.
Corticosteroids for treating optic neuritis.
Early pathological alterations of lower lumbar cords detected by ultrahigh-field MRI in a mouse multiple sclerosis model.
[Controlled research on multiple sclerosis treated with electroacupuncture and acupoint injection].
Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy (LHON)
The VP1 subunit of JC polyomavirus recapitulates early events in viral trafficking and is a novel tool to study polyomavirus entry.
Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis.
Endogenous opioids regulate the expression of inducible nitric oxide synthase by splenocytes.
Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam.
Oral dalfampridine improves standing balance detected at static posturography in multiple sclerosis.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Pages
« first
‹ previous
…
155
156
157
158
159
160
161
162
163
…
next ›
last »